This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Zimmer Biomet (ZBH) Hurt by EMEA's Slow Recovery Amid Pandemic
by Zacks Equity Research
Zimmer Biomet's (ZBH) leveraged capital structure is an added concern.
Quidel's (QDEL) QuickVue OTC COVID-19 Test Now Widely Available
by Zacks Equity Research
In-store and online availability of Quidel's (QDEL) QuickVue OTC COVID-19 Test is expected to meet the rising COVID-19 testing needs across the United States.
Thermo Fisher (TMO) Gains Government Contract for Pipette Tip
by Zacks Equity Research
Thermo Fisher (TMO) will co-invest with the U.S. government to build a new manufacturing center for pipette tips in North Carolina.
Hold Petco (WOOF) as It Rides on Continued Demand for Pet Care
by Sapna Bagaria
Petco (WOOF) by dint of its wide product and services portfolio, omni-channel presence and strategic initiatives is well poised to cash in on the expanding petcare industry.
AMN Healthcare (AMN) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about AMN Healthcare's (AMN) broad array of services.
Veeva (VEEV) MedTech Suite to Aid B. Braun Speed Up Trials
by Zacks Equity Research
Adoption of Veeva's (VEEV) unified suites of cloud applications is likely to provide a significant boost to the company's Veeva Development Cloud business.
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Varex Imaging, Omnicell, STAAR Surgical and IDEXX Laboratories
BD's (BDX) Latest Diagnostic System to Improve Lab Efficiency
by Zacks Equity Research
BD's (BDX) new system is expected to address labs' needs for high-volume processing and increases in efficiency.
4 MedTechs to Gain in 2H21 Beating the Delta Variant-Led Dip
by Urmimala Biswas
Investors can choose to invest in MedTech stocks like VREX, OMCL, STAA, and IDXX that have shown tremendous promise amid the pandemic.
Stock Market News for Aug 31, 2021
by Zacks Equity Research
The S&P 500 and the Nasdaq closed at record highs on Monday as investors flocked to technology and consumer discretionary shares, after the Federal Reserve¿¿¿s dovish stance on tapering its monetary stimulus last week.
Should JPMorgan Diversified Return U.S. Mid Cap Equity ETF (JPME) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for JPME
Idexx (IDXX) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Idexx (IDXX) possesses solid growth attributes, which could help it handily outperform the market.
Reasons to Hold on to Veeva Systems (VEEV) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Veeva Systems (VEEV) on its slew of partnerships and robust product adoptions.
Here's Why You Should Retain Integra (IART) Stock for Now
by Zacks Equity Research
Solid performance across the CSS and Tissue Technologies segments is driving the top line for Integra (IART).
Thermo Fisher's (TMO) Oncomine Dx Gets CDx Approval for TIBSOVO
by Zacks Equity Research
Thermo Fisher (TMO) receives FDA go-ahead for the Oncomine Dx Target Test as a CDx for Servier's ivosidenib tablets, TIBSOVO.
SmileDirectClub (SDC) Reels Under Rising Costs, Debt Woes
by Zacks Equity Research
SmileDirectClub (SDC) sees net operating cash outflow in the second quarter.
BD (BDX) Veritor At-Home COVID-19 Test Receives EUA From FDA
by Zacks Equity Research
EUA for BD's (BDX) At-Home COVID-19 test is expected to boost home testing to prevent outbreaks and limit the rise in COVID-19 cases from the Delta variant.
Here's Why You Should Retain BD (BDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about BD (BDX) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Invest In Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Continued adoption of Tandem Diabetes' (TNDM) t:slim X2 technology and international expansion of the Control-IQ technology add to the company's solid second-quarter performance.
Is IDEXX Laboratories (IDXX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Here's Why You Should Retain Masimo (MASI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) owing to its slew of product launches and regulatory approvals.
Here's Why You Should Retain PacBio (PACB) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about PacBio (PACB) owing to its slew of strategic deals and strength in its Sequel system.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and raised 2021 outlook.
Petco (WOOF) Q2 Earnings Beat on Continued Demand for Pet Care
by Zacks Equity Research
Petco (WOOF) Q2 earnings exceed estimates on buoyant demand for pet care products and services.
Intuitive Surgical (ISRG) Hits 52-Week High: What's Behind It?
by Zacks Equity Research
Investors are optimistic about Intuitive Surgical's (ISRG) strength in its da Vinci surgical system.